PPARG and Alzheimer disease: In a different study, oral treatment with PPARγ agonist pioglitazone reduced the Aβ levels within the cortex in the APPswe/PSEN1δE9 (APP/PS1) mice, another mouse model that accumulates Aβ plaques similar to neuropathological features presented in AD [22].